

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(formerly known as China Pharmaceutical Group Limited 中國製藥集團有限公司)

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board of Directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”) is pleased to announce that Mr. WANG Jinxu (“Mr. WANG”) was appointed as an executive director of the Company with effect from 10 June 2013.

Mr. WANG, aged 42, joined the Group in 1999 and is currently a senior vice president of the Group responsible for products research, development and production commercialisation. Mr. WANG holds a bachelor’s degree in chemistry from Hebei University, a master’s degree in chemical engineering from Hebei University of Technology and a doctorate in chemical engineering from Tianjin University, and has more than 15 years of technical and management experience in the pharmaceutical industry. Mr. WANG has not held any directorship in any public listed companies in the last three years. Save as disclosed above, Mr. WANG has not held any other positions with the Group.

Mr. WANG has entered into a service contract with the Company for a period of three years commencing from 10 June 2013 and his appointment is subject to retirement and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. WANG is entitled to receive a monthly salary of RMB50,000 and an annual director’s fee of HK\$60,000. He is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined having giving consideration to the prevailing market practice, the Company’s remuneration policy and his level of responsibility.

As at the date of this announcement, Mr. WANG has personal interests in share options granted under the Company’s share option scheme to subscribe for 3,000,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance. Mr. WANG does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company. Save as disclosed above, Mr. WANG confirmed that there is no other information required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited and there is no other matter relating to his appointment which needs to be brought to the attention of the shareholders of the Company

By order of the board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 10 June 2013

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo and Mr. WANG Jinxu as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. HUO Zhenxing, Mr. QI Moujia, Mr. GUO Shichang, Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo and Mr. ZHANG Fawang as independent non-executive directors.